← All trials
NCT07063680
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- May 31, 2028
- Completion date
- May 31, 2028
- First posted
- Jul 14, 2025
- Last posted
- Jul 14, 2025
- Enrollment
- 390
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BurgundyLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.